Live Breaking News & Updates on Eisai co ltd

Stay informed with the latest breaking news from Eisai co ltd on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Eisai co ltd and stay connected to the pulse of your community

World Dementia Council seeks Alzheimer's action in next 10 years

Europe may still await its first disease-modifying Alzheimer’s drug after the EMA postponed its decision on Leqembi (lecanemab, Biogen Inc./Eisai Co. Ltd) on March 22, but leading members of the World Dementia Council were in an optimistic mood when they convened in London four days later.

London , City-of , United-kingdom , Lenny-shallcross , World-dementia-council , Ltd-on , Biogen-inc-eisai-co , Biogen-inc , Biogen-inc- , Eisai-co-ltd- , Alzheimers-disease , Lecanemab

Hong Kong stocks rally as Nikkei 225 falls

Stocks in the Asia-Pacific region mostly increased Tuesday, Feb. 6. Hong Kong stocks rose, with the Hang Seng Index up 4.0% at 16,136.87, while Japan's...

Hong-kong , Japan , Hang-seng-index , Article-normal , Pharmaceuticals , Healthcare-life-sciences , Financial-performance , Share-price-movement-disruptions , Corporate-industrial-news , Equity-markets , Commodity-financial-market-news

Japanese stocks rise for fifth session as Hong Kong stocks drop

Stocks in the Asia-Pacific region mostly climbed Friday, Jan. 12, the Japanese market showing a fifth day of increases. The Hang Seng Index of Hong Kong...

Hong-kong , Japan , Japanese , Article-normal , Financial-performance , Share-price-movement-disruptions , Corporate-industrial-news , Equity-markets , Commodity-financial-market-news , Content-types , Factiva-filters

Eisai wearable enables early Alzheimer's disease screening

Eisai Co. Ltd. and Oita University in Oita Prefecture, Japan, developed a first-of-its-kind machine learning model to predict amyloid beta accumulation in the brain using a wristband sensor. The model, which collects biological and lifestyle data from daily life, is expected to enable screening for brain amyloid beta accumulation to identify those at risk for Alzheimer's disease, particularly because amyloid beta begins to accumulate in the brain about 20 years before the onset of the disease.

Japan , Eisai-co , Oita-university-in-prefecture , Oita-university , Oita-prefecture , Eisai-co-ltd- , Machine-learning , Amyloid-beta , Alzheimers-disease , Legembi , Wearable-device

Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial

Merck & Co. Inc. and Eisai Co. Ltd. said Friday that a late-stage trial of Merck’s blockbuster cancer treatment Keytruda in combination with Eisai’s drug...

Gregory-lubiniecki , Merck-research-laboratories , Eisai-co , Merck-co , Article-normal , Pharmaceuticals , Merck-amp-co-inc- , Mrk , Eisai-co-ltd- , Esalf ,

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.

Boston , Massachusetts , United-states , Eisai-co , Eli-lilly-co , Biogen-inc , Drug-administration , Clinical-trials , Article-normal , Biotechnology-services , Pharmaceuticals

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.

Boston , Massachusetts , United-states , Drug-administration , Biogen-inc , Eisai-co , Eli-lilly-co , Clinical-trials , Article-normal , Biotechnology-services , Pharmaceuticals

Could Eisai's Leqembi approval be the trigger for drug price reform in Japan?

As pricing negotiations for Biogen Inc./Eisai Co. Ltd.’s newly approved Leqembi (lecanemab) for Alzheimer’s disease get underway at Japan’s Central Social Insurance Medical Council (Chuikyo), industry watchers see opportunity for potential drug price reform.

Japan-central-social-insurance-medical-council-chuikyo , Biogen-inc-eisai-co , Biogen-inc , Central-social-insurance-medical-council , Eisai-co-ltd- , Leqembi , Lecanemab , Alzheimers-disease , Chuikyo , Drug-pricing ,

Dato data lack upside for Gilead; Padcev 'must-win' does win

Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form the basis of global approval bids, as Astrazeneca plc with Daiichi Sankyo Co. Ltd. unveiled interim results from a study called Tropion-Breast01. Targeting trophoblast cell surface antigen 2, datopotamab deruxtecan (dato) hit the mark in progression-free survival for patients with hormone receptor-positive, HER2-low or negative breast cancer in the study called Tropion-Breast01.

Daiichi-sankyo-co , Astrazeneca , Daiichi-sankyo , Phase-iii , Merck-amp-co-inc- , Keytruda , Padcev , Astellas-pharma-inc- , Eisai-co-ltd- , Lenvima , Metastatic-urothelial-carcinoma

Dato data lack means upside for Gilead; Padcev 'must-win' does win

Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form the basis of global approval bids, as Astrazeneca plc with Daiichi Sankyo Co. Ltd. unveiled interim results from a study called Tropion-Breast01. Targeting trophoblast cell surface antigen 2, datopotamab deruxtecan (dato) hit the mark in progression-free survival for patients with hormone receptor-positive, HER2-low or negative breast cancer in the study called Tropion-Breast01.

Daiichi-sankyo-co , Astrazeneca , Daiichi-sankyo , Phase-iii , Merck-amp-co-inc- , Keytruda , Padcev , Astellas-pharma-inc- , Eisai-co-ltd- , Lenvima , Metastatic-urothelial-carcinoma